

SARCOID (Sarcoidosis, Neurosarcoidosis, Cardiac Sarcoid)

All Classes
(Updated 09/24/2025)

DISEASE/CONDITION	EVALUATION DATA	DISPOSITION
A. Pulmonary Stage 1 (lung involvement only)	<p>The AME should review a completed and signed Sarcoid or Sarcoidosis Status Summary from the pulmonologist OR a detailed clinical progress note which addresses all items.</p> <p>If all items fall into the “YES” column, the individual meets vision standards, and the AME has no concerns.</p>	<div style="background-color: green; color: white; text-align: center; padding: 5px;">ISSUE</div> <p>Annotate Block 60 and submit the evaluation to the FAA for retention in the file.</p>
B. Pulmonary Stage 2 or greater OR Other organ involvement such as <ul style="list-style-type: none"> • skin, • eye, • liver, • bone marrow, • spleen, • kidney, • musculoskeletal. OR Sarcoid with hypercalcemia All items marked with a ^ must be performed no more than 90 days prior to the AME exam.	<p>Submit the following for FAA review:</p> <ol style="list-style-type: none"> 1. Detailed clinical progress note^ (within the past 90 days) from a board-certified Pulmonologist, Rheumatologist or Internist, to include systems affected and physical exam emphasizing lung, heart, liver, spleen, and skin. Include a thorough neurological examination. Identify the current stage of pulmonary sarcoidosis, if present. 2. Labs^ <ul style="list-style-type: none"> • Complete Blood Count (CBC), • Complete Metabolic Panel (CMP), • Serum Calcium, and • Urinalysis. 3. Chest X-ray report^ and most recent chest CT report (if performed) 4. Pathology reports from all biopsies to confirm sarcoidosis diagnosis 5. Tuberculosis (TB) testing if pulmonary sarcoidosis is present. 6. Pulmonary Function Test (PFT) to include flow volume loops, spirometry, lung volumes, and DLCO^. 7. 6-minute walk test^ 8. Eye evaluation by an ophthalmologist^ 9. 12-lead ECG^ 10. Cardiac monitoring study of at least 24 hours, such as Holter monitor^ 11. Most recent brain MRI with contrast 	<div style="background-color: red; color: white; text-align: center; padding: 5px;">DEFER</div> <p>Submit the information to the FAA for a possible Special Issuance</p> <p>Annotate (elements or findings) in Block 60.</p>

<p>C. Cardiac sarcoidosis</p> <p>Or</p> <p>Nervous system involvement (Neurosarcoidosis)</p>	<p>Submit the following for FAA review:</p> <ol style="list-style-type: none"> 1. All items in Row B 2. Include any information that supports disease stability. 3. Items specified for cardiac or neurological sarcoidosis below. <p><u>Cardiac sarcoidosis</u> also submit:</p> <ul style="list-style-type: none"> • Detailed clinical progress note from a board-certified Cardiologist (within the past 90 days) • Report from the most recent echocardiogram • Report from the most recent Cardiac MRI • Cardiac monitoring study (event monitor) of at least 30 days <p><u>Neurologic sarcoidosis</u> is present also submit:</p> <ul style="list-style-type: none"> • Neurological Evaluation per FAA specifications (within past 90 days) • Brain MRI with contrast since initial diagnosis or most recent brain MRI if new symptoms have developed since last evaluation • All neuroimaging on CD in DICOM format • Lumbar puncture results (if performed) 	<div data-bbox="1224 96 1487 134" style="background-color: red; height: 18px; width: 100%;"></div> <p>DEFER</p> <p>Submit the information to the FAA for a possible Special Issuance</p> <p>Annotate (elements or findings) in Block 60.</p>
---	--	---